TFS Capital’s Anika Therapeutics ANIK Stock Holding History

TFS Capital’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-16,099	Closed	-$663K	–	893
2015 Q1	$663K	Buy	+16,099	New	+$651K	0.06%	458
2014 Q4	–	Sell	-64,896	Closed	-$2.38M	–	975
2014 Q3	$2.38M	Sell	64,896 -40,943	-39%	-$1.77M	0.21%	146
2014 Q2	$4.9M	Buy	105,839 +93,117	+732%	+$4.14M	0.39%	24
2014 Q1	$523K	Sell	12,722 -17,442	-58%	-$648K	0.03%	711
2013 Q4	$1.15M	Sell	30,164 -175,724	-85%	-$5.42M	0.05%	505
2013 Q3	$4.92M	Buy	205,888 +26,223	+15%	+$589K	0.22%	99
2013 Q2	$3.05M	Buy	+179,665	New	+$2.59M	0.13%	215

Other funds holding ANIK

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LCP

Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return

TFS Capital's ANIK Position: Q2 2015 in Review

TFS Capital sold out of Anika Therapeutics (ANIK) in Q2 2015, closing a stake of 16,099 shares — an estimated $663K sold.

TFS Capital first reported a position in ANIK in Q2 2013 and held it in 7 quarters. The position peaked at $4.92M in Q3 2013. 136 funds tracked by Wall St. Rank hold ANIK as of Q2 2015.

TFS Capital reported no remaining Anika Therapeutics position as of Q2 2015 after selling out during the quarter.
TFS Capital sold 16,099 Anika Therapeutics shares in Q2 2015, an estimated $663K.
TFS Capital first reported a position in Anika Therapeutics in Q2 2013 and held it in 7 quarters.
TFS Capital's Anika Therapeutics position peaked at $4.92M in Q3 2013.
136 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2015.

Based on TFS Capital's 13F filing for Q2 2015, filed 5 Aug 2015.